Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > LATEST
LATEST
-
REGULATORY Ensure Sustainable Drug Pricing for National Security: LDP Health Division Chief
November 21, 2025
-
REGULATORY Chuikyo Discusses Lower Prices for Low-Novelty Drugs, PMP Criteria, Re-Pricing
November 20, 2025
-
REGULATORY Chuikyo Split over How to Ease Negative Margins
November 20, 2025
-
REGULATORY Providers Urging Possible Price Measures over Packaging Misalignment
November 20, 2025
-
REGULATORY Providers Push to Expand 2% Buffer Zone in Drug Price Revisions as Costs Rise
November 20, 2025
-
REGULATORY Japan Moves to Advance “G1” Price Cuts by 5 Years under Proposed LLP Overhaul
November 20, 2025
-
BUSINESS Kyowa Kirin Debuts Crysvita Prefilled Syringe and Lumicef Auto-Injector in Japan
November 20, 2025
-
ACADEMIA 5-Year Cancer Survival Shows Wide Gap by Tumor Types, Gains Seen in Lymphoma: NCC
November 20, 2025
-
REGULATORY MHLW to Scrutinize Outcomes for 12 Firms Yet to Strike MFN Deals
November 20, 2025
-
BUSINESS Boehringer Sees Oncology as Pillar of Japan Business, Starting with Hernexeos
November 20, 2025
-
BUSINESS Nxera to No Longer Invest in Non-Priority Assets, Shifts 80% of Pipeline to Obesity and Metabolic Areas
November 19, 2025
-
REGULATORY Govt Weighs Additional Copays for OTC-Like Drugs in Economic Package
November 19, 2025
-
REGULATORY LDP Study Group Submits Emergency Proposal to Health Minister, Seeks 5% Drug Price Hike
November 19, 2025
-
BUSINESS Chugai to Absorb Renalys Pharma in Late December
November 19, 2025
-
ORGANIZATION PhRMA Chief Warns Japan Is Losing Its Appeal, Urges End to On-Patent Price Cuts
November 19, 2025
-
BUSINESS Nxera Unveils Restructuring Plan to Return to Profit, 15% Job Cuts in Japan and UK
November 18, 2025
-
BUSINESS Vital KSK to Repurpose Shield’s Iron Deficiency Drug for PAH in Japan
November 18, 2025
-
BUSINESS Lundbeck Files Anti-CGRP Antibody Eptinezumab in Japan
November 18, 2025
-
BUSINESS Nipro Files for Full Approval of Stemirac Cell Therapy
November 18, 2025
-
BUSINESS Dupixent 200 mg Pen Now Available in Japan: Sanofi
November 18, 2025
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…